Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 4/2018

01-04-2018 | Progress in Hematology

Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan

Authors: Hiroaki Miyoshi, Koichi Ohshima

Published in: International Journal of Hematology | Issue 4/2018

Login to get access

Abstract

The morbidity and mortality of disease vary according to the region and may also change over time. The morbidity and mortality of malignant lymphoma are also affected by differences in ethnicity, lifestyle habits, geographical area, and time period. Increasing research on malignant lymphoma has focused on its pathophysiology, diagnosis, and therapeutic treatment. Recent improvements in the accuracy of clinical study, technologies such as next-generation sequencing, and the development of targeted molecular agents have also resulted in a number of excellent studies. This review summarizes the epidemiology of malignant lymphoma and highlights novel studies on adult T-cell leukemia/lymphoma recently published in Japan.
Literature
1.
2.
Forman D, Ferlay J. The global and regional burden of Cancer. World Cancer Report (Stewart EW, Wild CP, edited). Lyon: International Agency for Research on Cancer; 2014. p. 16–53.
3.
Jaffe ES, Swerdlow SH, Vardiman JW. Haematopoietic and lymphoid malignancies. World Cancer Report (Stewart EW, Wild CP, edited). Lyon: International Agency for Research on Cancer; 2014. p. 482–94.
4.
Aoki R, Karube K, Sugita Y, Nomura Y, Shimizu K, Kimura Y, et al. Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001–2006. Pathol Int. 2008;58:174–82.CrossRefPubMed
5.
Lymphoma Study Group of Japanese Pathologists. The world health organization classification of malignant lymphomas in japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int. 2000;50:696–702.CrossRef
6.
Chihara D, Ito H, Izutsu K, Hattori M, Nishino Y, Ioka A, et al. Advance and stagnation in the treatment of patients with lymphoma and myeloma: analysis using population-based cancer registry data in Japan from 1993 to 2006. Int J Cancer. 2015;137:1217–23.CrossRefPubMed
7.
Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, et al. Distribution of lymphoid neoplasms in China: analysis of 4638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138:429–34.CrossRefPubMed
8.
Yoon SO, Suh C, Lee DH, Chi HS, Park CJ, Jang SS, et al. Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification. Am J Hematol. 2010;85:760–4.CrossRefPubMed
9.
Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126:2570–7.CrossRefPubMed
10.
Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116:1369–76.CrossRefPubMed
11.
Katsuya H, Shimokawa M, Ishitsuka K, Kawai K, Amano M, Utsunomiya A, et al. Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma. Blood. 2017;130:39–47.CrossRefPubMed
12.
Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Haematol. 1991;79:428–37.CrossRefPubMed
13.
Kataoka K, Iwanaga M, Yasunaga JI, Nagata Y, Kitanaka A, Kameda T, et al. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood. 2018;131:215–25.CrossRefPubMed
14.
Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46:171–5.CrossRefPubMed
15.
Nagata Y, Kontani K, Enami T, Kataoka K, Ishii R, Totoki Y, et al. Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood. 2016;127:596–604.CrossRefPubMedPubMedCentral
16.
Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458–64.CrossRefPubMed
17.
Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-Cell leukemia/lymphoma. J Clin Oncol. 2016;34:4086–93.CrossRefPubMed
18.
Narita T, Ishida T, Ito A, Masaki A, Kinoshita S, Suzuki S, et al. Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma. Blood. 2017;130:1114–24.CrossRefPubMed
19.
Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015;126:2193–201.CrossRefPubMedPubMedCentral
20.
Yokoyama S, Miyoshi H, Nishi T, Hashiguchi T, Mitsuoka M, Takamori S, et al. Clinicopathologic and prognostic implications of programmed death ligand 1 expression in thymoma. Ann Thorac Surg. 2016;101:1361–9.CrossRefPubMed
21.
Yokoyama S, Miyoshi H, Nakashima K, Shimono J, Hashiguchi T, Mitsuoka M, et al. Prognostic value of programmed death ligand 1 and programmed death 1 expression in thymic carcinoma. Clin Cancer Res. 2016;22:4727–34.CrossRefPubMed
22.
Miyoshi H, Kiyasu J, Kato T, Yoshida N, Shimono J, Yokoyama S, et al. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. Blood. 2016;128:1374–81.CrossRefPubMed
23.
Metadata
Title
Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan
Authors
Hiroaki Miyoshi
Koichi Ohshima
Publication date
01-04-2018
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2018
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-2430-6

Other articles of this Issue 4/2018

International Journal of Hematology 4/2018 Go to the issue

Progress in Hematology

Current status and progress of lymphoma management in China

Images in Hematology

Non-alcoholic steatohepatitis induced by induction chemotherapy for pediatric acute lymphoblastic leukemia

Original Article

Genetic analysis of a novel missense mutation (Gly542Ser) with factor XII deficiency in a Chinese patient of consanguineous marriage

Original Article

Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission

Case Report

Gene analysis of inherited antithrombin deficiency and functional analysis of abnormal antithrombin protein (N87D)

Images in Hematology

Marked erythroblastosis in myelodysplastic syndrome induced by gastric hemorrhaging
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits